|
|
Oragenics Inc (NYSE: OGEN) |
|
Price: $0.4990
$0.00 
-0.200%
|
| Day's High:
| $0.503600001335144
| Week Perf:
| -2.16 %
|
| Day's Low: |
$ 0.50 |
30 Day Perf: |
-7.59 % |
| Volume (M): |
22,788 |
52 Wk High: |
$ 1.45 |
| Volume (M$): |
$ 0 |
52 Wk Avg: |
$0.79 |
| Open: |
$0.50 |
52 Wk Low: |
$0.48 |
|
|
| Market Capitalization (Millions $) |
2 |
| Shares
Outstanding (Millions) |
4 |
| Employees |
3 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-10 |
| Cash Flow (TTM) (Millions $) |
8 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Oragenics Inc is a bio-pharmaceutical company that is involved in the development of novel therapeutics for the treatment of infectious diseases. The company is headquartered in the United States, and its main focus is to create high-quality products to address major global health concerns.
Oragenics Inc's core technology is based on a proprietary platform called Oral Care and Therapeutics (OCAT). This platform is designed to develop drugs to tackle oral diseases by targeting the specific bacteria that are responsible for causing them. The OCAT platform uses recombinant DNA technology to generate beneficial microbes that can compete with and eradicate pathogenic bacteria.
The company's lead product candidate is TerraCoV2, which is a COVID-19 vaccine that uses its OCAT platform to develop a protein expression technology to generate recombinant spike proteins. This vaccine candidate is in preclinical development.
Oragenics Inc is also developing AG013, an oral mucositis treatment that uses the OCAT platform to generate a live biotherapeutic product that produces human tissue repair factors. This drug candidate is currently in Phase II clinical trials.
Another product candidate in the company's pipeline is OG716, which is an oral care product aimed at reducing the risk of dental caries. This product is a bacteriocin that uses the OCAT platform to generate a peptide that can selectively kill specific pathogenic bacteria without harming the beneficial bacteria.
In addition to its product development efforts, Oragenics Inc has established several partnerships with leading research institutions and pharmaceutical companies. These collaborations are focused on leveraging the company's technology and expertise to advance the development of disease vaccines, therapeutics, and diagnostic tools.
Overall, Oragenics Inc is a leading bio-pharmaceutical company that is dedicated to developing innovative products to address major global health concerns. With a strong pipeline of products and ongoing collaborations, the company is well-positioned to make a significant impact on the field of infectious disease therapeutics.
Company Address: 9015 Town Center Parkway Lakewood Ranch 34202 FL
Company Phone Number: 286-7900 Stock Exchange / Ticker: NYSE OGEN
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Management Announcement
Published Thu, Mar 27 2025 12:30 PM UTC
Oragenics, Inc.: Pioneering Neurological Therapeutics Amidst a New Strategic VisionIn the rapidly evolving landscape of biotechnology, few companies have displayed the agility and foresight necessary to adapt and innovate as effectively as Oragenics, Inc. The Sarasota-based biotechnology firm has taken notable strides under the leadership of CEO Janet Huffman, making signifi...
|
| Shares
Published Mon, Dec 16 2024 1:09 PM UTC
Oragenics, Inc. Takes Strategic Steps: Preferred Shares Conversion and Successful Public Offerings Sarasota, FL September 5, 2024: Oragenics, Inc. (NYSE American: OGEN) continues to make significant strides in its mission to innovate within the pharmaceutical landscape, particularly in the field of neurological disorders. In a recent series of announcements, the company det...
|
| Clinical Study
Published Wed, Oct 9 2024 11:30 AM UTC
Oragenics, Inc. Makes Significant Progress in Concussion Drug Development Ahead of Phase II Trials Oragenics, Inc. (NYSE American: OGEN), a biopharmaceutical company based in Sarasota, Florida, has made significant strides in the development of innovative therapies for neurological conditions throughout 2024. The company recently provided an update on the progress of ONP-0...
|
| Product Service News
Published Tue, Oct 8 2024 12:45 PM UTC
In an era where neuroscience innovations continually redefine the boundaries of medical science, Oragenics Inc. a nascent trailblazer headquartered in Sarasota, Florida, has marked a pivotal milestone in its quest to revolutionize concussion treatment. On October 8, 2024, the company gleefully announced the successful completion of a landmark study of ONP-002, a novel therap...
|
| Financing Agreement
Published Thu, Sep 5 2024 8:31 PM UTC
Introductionnn
On September 5, 2024, Oragenics, Inc. (NYSE American: OGEN), an innovative biotech company specializing in intranasal pharmaceuticals for treating neurological disorders, announced the successful closing of its recent public offering. This transaction raised approximately $1.7 million through the issuance of 3,078,378 shares of common stock and p...
|
Fundamental Analysis
| Per Share |
Current |
| Earnings (TTM) |
-455.83 $ |
| Revenues (TTM) |
-
|
| Cash Flow (TTM) |
1.84 $ |
| Cash |
0.87 $
|
| Book Value |
0.83 $
|
| Dividend (TTM) |
0 $ |
| Efficiency
|
Current |
| Revenue per Employee
(TTM) |
- |
| Net
Income per Employee (TTM) |
-3,361,136 |
| Receivable Turnover Ratio (TTM) |
- |
| Inventory Turnover Ratio (TTM) |
- |
| Asset Turnover Ratio (TTM) |
- |
|
|
| Per Share |
|
| Earnings (TTM) |
-455.83 $
|
| Revenues (TTM) |
- |
| Cash Flow (TTM) |
1.84 $ |
| Cash |
0.87 $
|
| Book Value |
0.83 $ |
| Dividend (TTM) |
0 $ |
|
|
|
|
1.88%